Cargando…

Comparative Analysis of All-Cause Health Care Resource Utilization and Costs Among Venous Thrombosis Patients Without Cancer Prescribed Apixaban or VKAs in France

INTRODUCTION: The direct oral anticoagulant (DOAC) apixaban has shown to have non-inferior efficacy and better safety than vitamin K antagonists (VKAs) in patients with venous thromboembolism (VTE). We determined whether healthcare resource use (HCRU) and direct all-cause medical and non-medical cos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mokgokong, Ruth, Khachatryan, Artak, Quignot, Nadia, Chaves, Jose, Moniot, Audrey, Gusto, Gaelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309117/ https://www.ncbi.nlm.nih.gov/pubmed/35767124 http://dx.doi.org/10.1007/s12325-022-02200-7

Ejemplares similares

Effectiveness and Safety of Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism: A Nationwide Comparative Cohort Study in France
por: Bertoletti, Laurent, et al.
Publicado: (2022)

Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in France
por: Bertoletti, Laurent, et al.
Publicado: (2023)

Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS)
por: Touzeau, Cyrille, et al.
Publicado: (2021)

Development of New Deep Venous Thrombosis While on Apixaban
por: Sharma, Munish, et al.
Publicado: (2017)

Long-term Anticoagulation with Apixaban in Patients with Cerebral Venous Thrombosis
por: Bharath, Suman Preet, et al.
Publicado: (2023)

DOACs or VKAs or LMWH – What is the optimal regimen for cancer-associated venous thromboembolism? A systematic review and meta-analysis
por: Yamani, Naser, et al.
Publicado: (2022)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) Trial
por: Liu, Xianchen, et al.
Publicado: (2015)

Idiopathic pulmonary vein thrombosis treated with apixaban
por: Ngo, Dallis, et al.
Publicado: (2021)

An Updated Meta-Analysis of DOACs vs. VKAs in Atrial Fibrillation Patients With Bioprosthetic Heart Valve
por: Cao, Yalin, et al.
Publicado: (2022)

Post-TAVR patients with atrial fibrillation: are NOACs better than VKAs?—A meta-analysis
por: Wang, Lu, et al.
Publicado: (2023)

Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date
por: Trkulja, Vladimir
Publicado: (2016)

Apixaban/tocilizumab interaction: Venous thromboembolism: case report
Publicado: (2021)

Comparison of Apixaban and Low Molecular Weight Heparin in Preventing Deep Venous Thrombosis after Total Knee Arthroplasty in Older Adults
por: Jiang, Hui, et al.
Publicado: (2019)

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
por: Hendriks, Stephan V., et al.
Publicado: (2020)

Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia
por: Sattler, Laurent, et al.
Publicado: (2023)

Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis (ARM‐DVT): Methods of a prospective single‐arm management study
por: Woller, Scott C., et al.
Publicado: (2019)

New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs)
por: van Gorp, Rick H., et al.
Publicado: (2015)

Effectiveness and Safety of DOACs vs. VKAs in AF Patients With Cancer: Evidence From Randomized Clinical Trials and Observational Studies
por: Liu, Fuwei, et al.
Publicado: (2021)

Access Site Bleeding Complications with NOACs versus VKAs in Patients with Atrial Fibrillation Undergoing Cardiac Implantable Device Intervention
por: Spinoni, Enrico Guido, et al.
Publicado: (2022)

Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
por: Werth, Sebastian, et al.
Publicado: (2012)

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence
por: Zalpour, Ali, et al.
Publicado: (2014)

Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France
por: Belhassen, Manon, et al.
Publicado: (2022)

Left Ventricular Assist Device Pump Thrombosis in a Patient Treated with Apixaban
por: Alkhunaizi, Mansour A., et al.
Publicado: (2021)

Clinical Efficacy of Conventional Heparin Anticoagulation Combined with Apixaban in the Treatment of Patients with Cerebral Venous Thrombosis and Its Effect on Serum D-Dimer and FIB Expression
por: Dong, Xiaohui, et al.
Publicado: (2021)

Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands: Clinical and Economic Effects
por: de Jong, Lisa A., et al.
Publicado: (2018)

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
por: Reda, Sara, et al.
Publicado: (2022)

Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review
por: Mandernach, Molly W, et al.
Publicado: (2015)

Development of Pacemaker Lead Thrombosis in a Patient with Atrial Fibrillation during Apixaban Treatment
por: Adar, Adem, et al.
Publicado: (2019)

Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial
por: Woller, Scott C., et al.
Publicado: (2022)

Comparative Risk of Bleeding of Anticoagulant Therapy with Vitamin K Antagonists (VKAs) and with Non-Vitamin K Antagonists in Patients Undergoing Dental Surgery
por: Manfredini, Mattia, et al.
Publicado: (2021)

Thrombosis and bleeding outcomes in the treatment of cerebral venous thrombosis in cancer
por: Abelhad, Nadia I, et al.
Publicado: (2021)

Successful treatment with apixaban of sinus venous thrombosis due to pegylated asparaginase in a young adult with T cell acute lymphoblastic leukemia: case report and review of management
por: Talamo, Laura, et al.
Publicado: (2017)

Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability
por: Lee, Juseung, et al.
Publicado: (2023)

Modeling bioavailability to organs protected by biological barriers
por: Quignot, Nadia
Publicado: (2013)

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
por: Cornell, Robert Frank, et al.
Publicado: (2019)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
por: Cohen, Alexander T., et al.
Publicado: (2021)

Efficacy and Safety of NOACs Compared With VKAs for Patients With Atrial Fibrillation After Transcatheter Aortic Valve Implantation: A System Review and Meta-Analysis
por: Ge, Junye, et al.
Publicado: (2022)

Should the WHO Growth Charts Be Used in France?
por: Scherdel, Pauline, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uajg8fgceuhf4hp5qvnr9gkjvl